Quantcast

Industry news that matters to you.  Learn more

Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems

Reading time: 2 – 3 minutes

Ventana Medical Systems Inc., a member of the Roche Group, and Advanced Cell Diagnostics Inc. (ACD), announced today they have entered a worldwide co-promotion agreement for the first commercially available, fully automated RNA in situ hybridization (ISH) assay system capable of robust detection and visualization of virtually any expressed gene in routine clinical specimens at single-molecule sensitivity.

The two companies have partnered to automate this assay system on the Ventana Discovery series slide staining platforms. The product offerings are expected to become commercially available in the first quarter of 2012 and will initially be offered for research-use only (RUO) applications.

“Given the fact that the majority of biomarkers are discovered from genomic research and are RNA by nature, the automation of RNAscope represents an important milestone that will accelerate biomarker research into a new level of sophistication,” said Dr. Yuling Luo, founder, president and CEO of ACD. “RNAscope will become an equally indispensable tool alongside immunohistochemistry, fluorescence in situ hybridizationand polymerase chain reaction for researchers in life sciences and drug development.”

Luo said the ability to generate robust and reproducible results from routine clinical specimens “makes the technology a compelling platform for clinical diagnostic applications in the foreseeable future.

”The RNAscope FFPE Reagent Systems automated on the Ventana Discovery Ultra and Discovery XT offers researchers a powerful tool with unprecedented levels of performance.

“The combination of RNAscope reagent system and our sophisticated and flexible DISCOVERY platform and detection systems delivers a powerful solution for biomarker discovery and validation,” said Bill Crawford, director of marketing, Discovery, with Ventana. “It has significant potential to advance cell- and tissue-based biomarker analyses for future clinical and companion diagnostics development.”

RNA in situ hybridization is an indispensable method to analyze gene expression in the context of tissue architecture in areas of oncology, virology, and neuroscience research. RNAscope is an award-winning breakthrough technology that provides researchers the unique capability to interrogate the function and disease relevance of any expressed genes in situ, especially for the approximately 5,000 genes and 15,000 non-coding RNAs in the human genome where no other technologies can adequately address. In addition, RNAscope allows researchers to tap into the estimated 400 million clinically-annotated, archived formalin-fixed paraffin-embedded (FFPE) tissue specimens for retrospective clinical studies in translational research.

The Discovery XT and Discovery Ultra systems provide scientists and research professionals who require more than conventional IHC and ISH research methods with an array of fully automated applications, which improve flexibility and freedom and provide the necessary, reproducible results that optimize patient care.

Source: Ventana Medical Systems